Is there subclinical GCA in PMR pts? 50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all. Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually? Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh

#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal. Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe

Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk (vertebral & Maj OP Fx). 6144 infusions in 2594 pts, shows risk if delay is >16wks (long delay), but not if 4-16wks #EULAR20 SAT0453 https://t.co/DkJK3dHeRN https://t.co/r7ckpSF6PA

• https://bit.ly/2z6UhnA

H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD

• https://bit.ly/3eXAaYu

Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19 Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups) #EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9

VTE elevated risk is assoc up to 1 yr after high disease activity in RA 1% over 1 yr of active RA will get VTE OP0034 Data from Swedish popn study implications irrespective for which Rx pt gets? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR20 #eular2020 https://t.co/A7mWoYZI9S

RA pts are at risk of pneumonia, & inflamed lung mucosa can produce RF/CCP. Are these linked via subclinical lung injury? Seropos RA pts @BrighamWomens have double the pneumonia risk post-adjustment. We're still learning more about RF... @jeffsparks OP0111 #EULAR2020 @RheumNow https://t.co/C3CYpXABGc

GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail. Large Israeli database says there are links (EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why? OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah

Tenosynovitis is underrated in RA. A nice reminder from an Argentinian group, who USS scanned 90 RA pts in clinical remission >3m and followed them for 12m. Subclinical synovitis did not predict flares, but subclinical tenosynovitis did (adj OR 9.8) THU0119 #EULAR2020 @RheumNow https://t.co/kcle8qyQbI

Physician global assessment in RA is a murky beast, which we should standardise better (especially interrater). Portuguese cross-sectional (n = 392): SJC/CRP/HAQ/PGA did not fully explain it. What are we capturing, and does it matter? THU0111 #EULAR2020 @Janetbirdope @RheumNow https://t.co/krL2yFIl8a

Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing). It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab! @DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd

JAKi and VTE from @WHO VigiBase @UMCGlobalSafety Why the difference between Europe and US? There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM

RA isn't just a disease of joints & tendons: muscle is abnormal even at diagnosis. Changes throughout disease seen on MRI: T2, fatty infiltration, muscle volume all vary at different stages. Plenty more to understand/optimise! @LeedsBRC @DrAiLynTan OP0332 #EULAR2020 @RheumNow https://t.co/PwjLuZ1wcL https://t.co/QSYZALfi29

• Muscle Deterioration due to Rheumatoid Arthritis

I mean, the EULAR recommendations for management of early arthritis are tough: "1. Patients presenting arthritis... should be referred to, and seen by, a rheumatologist, within 6 weeks after the onset of symptoms" Does it matter though? https://t.co/wJkVHQZqjs

• https://twitter.com/drdavidliew/status/1268830312869400576?s=20

Outcome measures => Validity and reliability from @sofiaramiro82 #EULAR2020 @RheumNow https://t.co/M3XIDsTK39